Australia to have new biologicals framework in 2010
This article was originally published in RAJ Devices
Australian legislation to implement a new regulatory framework for human cellular and tissue based therapy products (HCTs) and other emerging biological therapies has been tabled in the House of Representatives1.
You may also be interested in...
The European Medicines Agency will use feedback from two workshops in September to clarify what data protection issues must be addressed to allow for the secondary use of health and medical data when it comes to developing, monitoring and evaluating medicines.
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.